Early intervention and prevention therapies for Alzheimer's disease
概要
Acta Pharmaceuticals, founded in 2022 in Boston, builds on the research of Dr. Rudolph E. Tanzi. Its lead program is GSM-779690T, an oral gamma-secretase modulator in a Phase 1 study in healthy adults. A second program tests drug combinations identified in human brain cell models.